Altogether, the implication of COX-2/prostaglandin signalization in VM formation by highly aggressive breast cancer cells opens new avenues for the use of COX-2/EP4 as a therapeutic target in breast cancer. This evidence concerns the gene PTGER2 and breast cancer.